Therefore only the DNA sample of the pathogen as well as a blood sample of a healthy person are nessessary. This development is of particular interest
in the case of frequently mutating pathogens such as HIV or influenza pathogens, as is said in a current press release within the awarding of the
"Elevator Pitch BW 2014/2015"  sponsored by the Ministry of Finance and Economics Baden-Württemberg.

For the development of "immune2day" the team of Dr. Günter Roth has already received the Freiburg Innovation Prize 2015.

For more information:
www.elevatorpitch-bw.de/events/stuttgart2/immune2day
www.freigem.org
www.zbsa.uni-freiburg.de/projects/ag-roth
www.rsc.org/competitions/emerging-tech

Press Release:
https://www.pr.uni-freiburg.de/pm/2015/pm.2015-06-23.90